Using reverse phase protein array (RPPA) analyses, we show that Ph+ALL patients have higher expression of phospho-ErbB2 compared to Ph−ALL, and that the ErbB kinase inhibitors canertinib and lapatinib abrogate proliferative signaling while promoting apoptotic signaling. This evidence concerns the gene ERBB2 and acute lymphoblastic leukemia.